Cancer diagnostics firm Nucleix plans European market expansion

Cancer diagnostics company Nucleix is planning to scale up commercial activities in Europe for its bladder test Bladder EpiCheck. The Israeli firm told Medtech Insight it is currently in advanced negotiations with distributors to expand the test’s commercial reach.

SOCIAL MEDIA

Subscribe to one of our social media channels

close

Subscription Confirmation Required

Go to your email inbox

Go to your email inbox

Go to the inbox of the email
address you just used to sign up.

Open the confirmation email

Open the confirmation email

Find the email sent by us. It has the subject line
“Nucleix: Please Confirm Subscription” and I
sent from “info@nucleix.com”.

Click the confirmation link

Click the confirmation link

Click on the link inside the
email and you’re good to go.

GOT IT !